We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration (SiCord)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04636853
Recruitment Status : Completed
First Posted : November 19, 2020
Last Update Posted : January 11, 2023
Sponsor:
Information provided by (Responsible Party):
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The study will provides the enrollment of patients with genetic retinal dystrophies with primary rod impairment and dry age-related macular degeneration (Geographic type) A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.

A complete morpho-functional ophthalmological evaluation will be performed in all patients at each control.


Condition or disease Intervention/treatment Phase
Retinitis Pigmentosa Dry Age-related Macular Degeneration Biological: Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) Phase 3

Detailed Description:

All patients underwent genetic evaluation and they reported different types of mutations that induce anatomic-functional impairment of the rods.

Patients affected by bilateral dry age-related macular degeneration (Geographic type) will be recruited as well.

After selecting the patients to be enrolled, the study will proceed with the vitrectomy surgery and subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) provided by the Umbilical Cord Bank according to the procedures provided for by the current legislation on blood components for non-transfusion use.

A complete ophthalmological examination will be performed at 1, 3, 6, and 12 months. They will include:

  • Anterior segment biomicroscopy
  • direct and indirect ophthalmoscopy
  • ETDRS visual acuity assessment
  • intraocular pressure measurement
  • optical coherence tomography (OCT)
  • OCT Angiography (OCTA)

The following assessments will be performed at baseline and at 6 and 12 months.

  • Microperimetry
  • Electroretinogram (ERG)
  • Visually evoked potential (VEP)
  • contrast sensitivity (MARS tables)
  • Goldmann perimetry

Some morpho-functional data will also be collected in the contralateral eye and used as the control group.

To ensure the best safety for the patient, the first 5 eyes will be separated by a minimum of 20 days in order to observe the post-surgical evolution.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cord Blood Platelet-rich Plasma (CB-PRP) in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
Actual Study Start Date : December 23, 2020
Actual Primary Completion Date : December 1, 2021
Actual Study Completion Date : December 2, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Affected Individual
A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.
 Biological: Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)

A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.

A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) morphological changes [ Time Frame: 3 years ]
    Differences in structural optical coherence tomography (OCT) and OCT Angiography (OCTA) images


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Retinal dystrophies with compromised rods (only for RP patients)
  • Visual Field (Manual Goldmann) V / 4e < 30 ° (only for RP patients)
  • Best corrected visual acuity > Light perception
  • Known genotype
  • No or minimal opacity of ocular media
  • No concomitant ocular (eg glaucoma, amblyopia)
  • Dry Age-related Macular Degeneration (Geographic type)

Exclusion Criteria:

  • Age<18 years
  • Pregnancy
  • Previous inflammatory / infectious events involving the eyes
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04636853


Locations
Layout table for location information
Italy
Alfonso Savastano
Rome, Italy, 00168
Sponsors and Collaborators
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Investigators
Layout table for investigator information
Principal Investigator: Alfonso Savastano Fondazione Policlinico Universitario A. Gemelli, IRCCS
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Layout table for additonal information
Responsible Party: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ClinicalTrials.gov Identifier: NCT04636853    
Other Study ID Numbers: 3417
First Posted: November 19, 2020    Key Record Dates
Last Update Posted: January 11, 2023
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fondazione Policlinico Universitario Agostino Gemelli IRCCS:
Cord blood platelet-rich plasma
Retinitis pigmentosa
Dry Age-related Macular degeneration
Macular Geographic Atrophy
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinitis
Retinitis Pigmentosa
Retinal Degeneration
Retinal Diseases
 Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Genetic Diseases, Inborn